Dr. Têtu is professor emeritus at the Faculty of Medicine of Laval University and a regular researcher in the Oncology axis of the CHU Research Centre of Quebec since 1986. Since the beginning of his career, in addition to his clinical practice and research activities, particularly as a FRSQ senior clinical researcher grant holder, he held various executive positions such as head of the Division of Pathology in the Department of Molecular Biology, Medical Biochemistry and Pathology, Director of the Clinician-Scientist Residency Program and Graduate Program in Clinical Epidemiology, Medical Director of RUIS Telepathology Project at Laval University, Chief of Pathology Services at CHUQ and CHA, Assistant Director of Clinical Research at CHUQ Research Centre, Chair of the Advisory Committee on Anatomical Pathology at the Quebec Cancer Board (Ministry of Health) and Chair of the membership committee of the Canadian Association of Pathologists.
His research themes are:
Clinical validation of new tumor markers
His studies aim to validate tumor markers identified as potentially interesting for predicting the evolution of cancers. These studies are applied to cohorts of patients using histopathological approaches, and therefore involve expertise in cellular and molecular biology, pathology and epidemiology. Several studies use samples from a tumor bank that he has been developing for over 20 years.
Studying the benefits and challenges of using telepathology
Telepathology is a technology that Dr. Têtu has helped to introduce in eastern Quebec, and allows the pathologist to establish remote diagnostics, mainly in oncology. Collaborations with experts in information technology assessment, applied in telemedicine, help identify the socio-political, organizational, clinical, professional, legal and technological benefits and challenges related to the introduction of telepathology.
1050, chemin Sainte-Foy
Service d'anatomopathologie et de cytologie
Canada G1S 4L8
Genome-wide germline correlates of the epigenetic landscape of prostate cancer.Journal Article
Nat Med, 25 (10), pp. 1615-1626, 2019, ISSN: 1078-8956.
The Immune Landscape of Cancer.Journal Article
Immunity, 51 (2), pp. 411-412, 2019, ISSN: 1074-7613.
Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level.Journal Article
Nutrients, 11 (7), 2019, ISSN: 2072-6643.
Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.Journal Article
Pathol Res Pract, 215 (6), pp. 152369, 2019, ISSN: 0344-0338.
The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.Journal Article
World J Urol, 37 (5), pp. 789-798, 2019, ISSN: 0724-4983.
The Proteogenomic Landscape of Curable Prostate Cancer.Journal Article
Cancer Cell, 35 (3), pp. 414-427.e6, 2019, ISSN: 1535-6108.
Widespread and Functional RNA Circularization in Localized Prostate Cancer.Journal Article
Cell, 176 (4), pp. 831-843.e22, 2019, ISSN: 0092-8674.
Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.Journal Article
BJU Int, 123 (4), pp. 624-631, 2019, ISSN: 1464-4096.
Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.Journal Article
Drug Metab Dispos, 47 (5), pp. 444-452, 2019, ISSN: 0090-9556.
Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.Journal Article
PLoS ONE, 14 (6), pp. e0218621, 2019.